A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.

Autor: Flores-Martín JF; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain. josefloresmartin@gmail.com.; Unidad de Gestión Clínica de Urología, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain. josefloresmartin@gmail.com.; Unidad de Gestión Clínica de Urología, Complejo Hospitalario Universitario de Jaén, Jaén, Spain. josefloresmartin@gmail.com., Perea F; Departamento de Bioquímica, Biología Molecular e Inmunología III, Facultad de Medicina, Universidad de Granada, Granada, Spain., Exposito-Ruiz M; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.; Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO), Granada, Spain., Carretero FJ; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.; Departamento de Bioquímica, Biología Molecular e Inmunología III, Facultad de Medicina, Universidad de Granada, Granada, Spain., Rodriguez T; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.; Departamento de Bioquímica, Biología Molecular e Inmunología III, Facultad de Medicina, Universidad de Granada, Granada, Spain., Villamediana M; Departamento de Bioquímica, Biología Molecular e Inmunología III, Facultad de Medicina, Universidad de Granada, Granada, Spain.; Unidad de Laboratorio Clínico, Hospital Universitario Virgen de las Nieves, Granada, Spain., Ruiz-Cabello F; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.; Departamento de Bioquímica, Biología Molecular e Inmunología III, Facultad de Medicina, Universidad de Granada, Granada, Spain.; Unidad de Laboratorio Clínico, Hospital Universitario Virgen de las Nieves, Granada, Spain., Garrido F; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.; Departamento de Bioquímica, Biología Molecular e Inmunología III, Facultad de Medicina, Universidad de Granada, Granada, Spain.; Unidad de Laboratorio Clínico, Hospital Universitario Virgen de las Nieves, Granada, Spain., Cózar-Olmo JM; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.; Unidad de Gestión Clínica de Urología, Hospital Universitario Virgen de las Nieves de Granada, Granada, Spain., Aptsiauri N; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.; Departamento de Bioquímica, Biología Molecular e Inmunología III, Facultad de Medicina, Universidad de Granada, Granada, Spain.
Jazyk: angličtina
Zdroj: Annals of surgical oncology [Ann Surg Oncol] 2019 Aug; Vol. 26 (8), pp. 2631-2639. Date of Electronic Publication: 2019 Apr 22.
DOI: 10.1245/s10434-019-07371-2
Abstrakt: Background: Tumor human leukocyte antigen class I (HLA-I) expression plays an important role in T cell-mediated tumor rejection. Loss of HLA-I is associated with cancer progression and resistance to immunotherapy, including antibodies blocking programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) signaling. Our objective was to analyze a correlation between HLA-I, tumor immune infiltration, and PD-L1/PD-1 axis in bladder cancer in association with the clinicopathologic features of patients.
Methods: We analyzed 85 cryopreserved bladder tumors by immunohistochemistry to investigate the expression of HLA-I, PD-L1, PD-1, CD3, CD8, and CXC chemokine receptor 4 (CXCR4). The results were correlated with tumor stage and other clinicopathologic variables of patients.
Results: We found a strong positive correlation between tumor HLA-I expression and infiltration with CD3+ and CD8 + T cells. PD-L1 expression was positive in 15.5% of tumors and heterogeneous in 40.5%, and was linked to a more advanced tumor stage. The majority of HLA-I-positive/heterogeneous tumors also expressed PD-L1 and PD-1, which were significantly correlated with each other and with lymphocyte infiltration. Interestingly, the analysis of the simultaneous expression of both markers revealed that 85.2% of tumors with a positive/heterogeneous HLA-I phenotype and negative for PD-L1 were mostly non-invasive, representing a 'tumor rejection' immune phenotype.
Conclusions: High tumor HLA-I expression with absence of PD-L1 provides bladder cancer with an immune rejection mechanism. Evaluation of PD-L1 and HLA-I together should be considered in bladder cancer and may provide a new predictive biomarker of tumor invasiveness and of the response to 'immune checkpoint' therapy.
Databáze: MEDLINE
Externí odkaz: